title: Should busulfan-containing regimen be avoided for young female patients undergoing hematopoietic stem cell transplantation?
authors.forename: S
authors.initials: S
authors.lastname: Okuda
authors.forename: M
authors.initials: M
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Terasako
authors.forename: S
authors.initials: S
authors.lastname: Kako
authors.forename: K
authors.initials: K
authors.lastname: Oshima
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
mesh_terms: D000328:Adult; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D010053:Ovary / Q000187:drug effects*; D011247:Pregnancy; D019172:Transplantation Conditioning
chemical_list: D019653:Myeloablative Agonists; D002066:Busulfan